Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
2020 · Nature Communications · 143 citations
https://doi.org/10.1038/s41467-020-16991-2
L
Lucía Barbier‐Torres
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
51
Papers
1.5K
Citations
22
h-index
27
i10-index
Lucía Barbier‐Torres is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Liver Disease Diagnosis and Treatment & Folate and B Vitamins Research & Cancer, Hypoxia, and Metabolism. The author has an h-index of 22, co-authored 44 publications.
ORCID: 0000-0002-7675-2888Papers by this author
worksThe mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury
2017 · Nature Communications · 107 citations
https://doi.org/10.1038/s41467-017-01970-x
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease
2019 · Molecular Metabolism · 47 citations
https://doi.org/10.1016/j.molmet.2019.08.008
MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis
2018 · Cell Death and Disease · 46 citations
https://doi.org/10.1038/s41419-018-1014-y
Depletion of mitochondrial methionine adenosyltransferase α1 triggers mitochondrial dysfunction in alcohol-associated liver disease
2022 · Nature Communications · 37 citations
https://doi.org/10.1038/s41467-022-28201-2
Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder
2023 · Drug and Alcohol Dependence · 9 citations
https://doi.org/10.1016/j.drugalcdep.2023.109822
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat